Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/21/2025

Dual Antiplatelet Therapy for Stroke-Like Symptoms

Immediate Management Based on Stroke Severity

  • The American Heart Association recommends dual antiplatelet therapy with aspirin and clopidogrel for patients with high-risk TIA (ABCD2 score >4) or minor stroke (NIHSS 0-3) of noncardioembolic origin, initiated within 24 hours and continued for 21-30 days, followed by monotherapy 1
  • For high-risk TIA or minor stroke, loading doses of clopidogrel 300-600 mg plus aspirin 160 mg should be given immediately after brain imaging excludes hemorrhage, with maintenance therapy of aspirin 81 mg plus clopidogrel 75 mg daily for 21-30 days 1
  • Dual antiplatelet therapy should be started within 24 hours of symptom onset, ideally within 12 hours, and before ED discharge, with a switch to monotherapy after 21-30 days 1
  • The evidence supporting dual antiplatelet therapy is robust, with the POINT trial demonstrating a reduction in ischemic stroke risk from 6.3% to 4.6% (HR 0.72, p=0.01), preventing 15 ischemic strokes per 1000 patients treated 1

Key Contraindications and Timing Restrictions

  • Dual antiplatelet therapy should not be used in patients with active bleeding or intracranial hemorrhage, and should be delayed until 24-hour post-thrombolysis scan excludes hemorrhage after thrombolysis (alteplase) 1
  • Long-term dual therapy (>30 days) increases bleeding and mortality without additional benefit, and should be avoided 4
  • Cardioembolic stroke requires anticoagulation instead of antiplatelets 3, 5

Risk Stratification for Dual Therapy Decision

  • Dual antiplatelet therapy is recommended for patients with high-risk features (ABCD2 score >4 or minor stroke with NIHSS 0-3) and noncardioembolic etiology (no atrial fibrillation, mechanical valve, or cardiac thrombus) 1, 3
  • Aspirin monotherapy is recommended for patients with moderate-to-severe stroke (NIHSS >3), cardioembolic source, or presentation >24 hours after symptom onset 1, 3, 5

Practical Implementation Details

  • For patients with dysphagia, enteral tube administration of aspirin 80 mg plus clopidogrel 75 mg daily, or rectal route administration of aspirin 325 mg suppository daily, can be considered 1
  • Proton pump inhibitors, such as dexlansoprazole, lansoprazole, or pantoprazole, can be used for GI protection in patients at higher GI bleeding risk on dual therapy 1

Common Pitfalls to Avoid

  • Dual therapy should not be continued beyond 30 days unless there is a separate indication, as this increases major bleeding without additional stroke prevention benefit 1, 4
  • Dual antiplatelet therapy should not be used as a substitute for anticoagulation in patients with atrial fibrillation, as the combination carries similar bleeding risk to warfarin without the stroke prevention benefit 5
  • Delaying dual therapy initiation beyond 24 hours significantly diminishes its benefit, and should be avoided 1